Moderna articles
-
Moderna halts plans to build Kenya vaccine plant as Covid shot demand plunges
Moderna's decision aligns with its broader effort to cut costs by resizing its Covid vaccine-manufacturing footprint.
-
Moderna’s ‘Disappointing’ Pull Back From Kenya Highlights Complexity Of Expanding Vaccine Manufacturing In Africa
“Disappointed” is how the Africa Centres for Disease Control and Prevention phrased its response to pharmaceutical company Moderna “pausing” its Kenyan mRNA vaccine manufacturing facility. Moderna’s decision is yet another example of how complex it is to kickstart vaccine manufacturing on the continent – an essential component to safeguard Africans against future pandemics on the […]
-
Insider Selling: Moderna, Inc. (NASDAQ:MRNA) Director Sells 15,000 Shares of Stock
Moderna, Inc. (NASDAQ:MRNA - Get Free Report) Director Noubar Afeyan sold 15,000 shares of the company's stock in a transaction on Wednesday, April 10th. The shares were sold at an average price of $107.12, for a total transaction of $1,606,800.00. Following the completion of the transaction, the director now owns 2,071,931 shares of the company's stock, valued at $221,945,248.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC...